LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients.

This final part of the video informative series focuses on LIVERFASt, a non-invasive AI driven technology that helps provide quantitative assessments of lesions (fibrosis, steatosis, inflammatory activity).

Dr Mona Munteanu, the Fibronostics Chief Scientific Officer, and Dr Imtiaz Alam, a Hepatologist, share their knowledge and experience of how LIVERFASt can be useful not only for screening, but also staging. LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients.